Iron deficiency is very common in patients with heart failure, affecting between one third to a half of all patients. IRONMAN will help determine if treatment with intravenous iron can help patients feel better, and reduce the risk of being hospitalized for heart failure or dying.

In this interview, Professor Paul Kalra MD, FRCP and Roger S. Blumenthal MD, FACC discuss IRONMAN – Randomized Trial of Intravenous Ferric Derisomaltose in HFrEF.

Related References:

• The main IRONMAN manuscript will be published in the Lancet simultaneous with the presentation at the AHA (5th November 2022)

Clinical Topics: Heart Failure and Cardiomyopathies, Acute Heart Failure

Keywords: ACCELLite, Heart Failure, Anemia, Iron-Deficiency

< Back to Listings